Former pharmaceutical champion Pfizer (PFE) , down 52% from its December 2021 all-time high, is judged to be in the throes of a "bearish-to-bullish" Reversal.
Pfizer, the laggard the past year: Is now... Pfizer, the leader the past month: By our work, PFE represents a compelling "value play".
And with a 5.73% dividend yield, one "gets paid" to wait as the stock continues to bottom.
THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET.
BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.
Persons:
Carter Braxton Worth
Organizations:
Pfizer, pharma, Pharmaceuticals Industry Group, CNBC, NBC UNIVERSAL